The global methicillin-resistant staphylococcus aureus (MRSA) drugs market, by Drug class (Glycopeptides and Lipoglycopeptides, Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 922.2 Million in 2018, and is expected to exhibit a CAGR of 4.1%, during the forecast period (2018-2026), as highlighted in a new report published by . Key players in the market are involved in expanding indication of its approved drugs. For instance, in 2016, Allergan Plc. received the U.S. Food and Drug Administration (FDA) approval for its supplemental new drug application (sNDA) to update the label of Dalvance (dalbavancin) for injection. The updated label includes a single dose administered as a 30-minute intravenous (IV) infusion of DALVANCE for treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible gram-positive bacteria in adults, including infections caused by methicillin-resistant staphylococcus aureus (MRSA). Implementation of such strategies is expected to drive the methicillin-resistant staphylococcus aureus (MRSA) drugs market growth. Increasing focus of manufacturers on strategic acquisitions is expected to contribute to the growth of the methicillin-resistant staphylococcus aureus (MRSA) drugs market. For instance, in May 2018, Cipher Pharmaceuticals Inc. acquired Xydalba, the product from Canadian business portfolio of Cardiome Pharma Corp. Moreover, in 2014, Merck & Co., Inc. acquired Cubist Pharmaceuticals, Inc. Through this acquisition, Cubist has helped Merck expand its product portfolio. Browse 29 Market Data Tables and 31 Figures spread through 164 Pages and in-depth TOC on "Global Methicillin-resistant Staphylococcus aureus (MRSA) Drugs market, by Drug class, (Glycopeptides and Lipoglycopeptides, Oxazolidinones, Lipopeptides, Cephalosporin, Tetracycline, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026" To know the latest trends and insights related to global methicillin-resistant staphylococcus aureus (MRSA) drugs market, click the link below: https://www.coherentmarketinsights.com/ongoing-insight/methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-1538 Manufacturers are focusing on product development and launches for treatment of infection associated with methicillin-resistant staphylococcus aureus (MRSA), which is expected to drive growth of the global methicillin-resistant staphylococcus aureus (MRSA) drugs market. For instance, in February 2019, Paratek Pharmaceuticals, Inc. launched NUZYRA (omadacycline) in the U.S. market. The drug is designed for a once-daily intravenous and oral administration, and is specifically designed to overcome tetracycline resistance and exhibits activity across a spectrum of bacteria, such as gram-positive, gram-negative, atypicals, and other drug-resistant strains. Moreover, increasing adoption of growth strategies such as partnerships is expected to result in significant growth of the MRSA drugs market. In March 2019, Melinta Therapeutics entered into an exclusive license, supply, and distribution agreement with Hikma Pharmaceuticals. The deal includes Melinta’s intravenous and oral formulations of antibiotic Baxdela (delafloxacin), across Middle East and North Africa markets. Key Takeaways of the Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs market:

  • The global methicillin-resistant staphylococcus aureus (MRSA) drugs market is expected to expand at a CAGR of 4.1% during the forecast period (2018–2026) owing to development of prominent drug molecules for treatment of infections associated with methicillin-resistant staphylococcus aureus (MRSA)
  • Increasing product launches by key players to expand their portfolio of nutrition testing kits is expected to drive the global methicillin-resistant staphylococcus aureus (MRSA) drugs market growth. For instance, in 2017, Cardiome Pharma Corp. launched Xydalba in Sweden, Finland, and the Republic of Ireland. Xydalba is approved by the European Medicines Agency (EMA) for treatment of acute bacterial skin and skin structure infections (ABSSSIs) in adults.
  • Major players operating in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market include Merck & Co., Inc., Pfizer, Inc., Allergan Plc., Teva Pharmaceutical Industries ltd., Melinta Therapeutics, Inc., Cumberland Pharmaceuticals Inc., Nabriva Therapeutics Plc. Paratek Pharmaceuticals, Inc., Debiopharm International S.A., and Innovation Pharmaceuticals Inc.

 

 

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us: